BIBF 1202-^{13}C,d_3

Cat. No.:	HY-15992S
Molecular Formula:	$C_{29}{}^{13}CH_{28}D_3N_5O_4$
Molecular Weight:	529.61
Target:	VEGFR; Isotope-Labeled Compounds
Pathway:	Protein Tyrosine Kinase/RTK; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BIBF 1202-^{13}C,d_3 is the ^{13}C- and deuterium labeled BIBF 1202. BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[76]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.

[2]. Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumorefficacy. Cancer Res. 2008 Jun 15;68(12):4774-82.

[3]. Stopfer P, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011 Apr;41(4):297-311.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA